I think, don't know for sure, that the hold matters because other indication studies and trials will use the safety data from the HIV trials so they do not need to re-do the safety part for NASH etc..

However, if it is just a study and not a phase 3 trial, not sure why the safety part is really needed. could be how the protocols are written, cant base safety on data that is currently on clinical hold.